Credit Suisse’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-165,770
| Closed | -$35K | – | 4312 |
|
|
2018
Q1 | $35K | Buy |
165,770
+47,000
| +40% | +$43.3K | ﹤0.01% | 3910 |
|
|
2017
Q4 | $153K | Sell |
118,770
-124,099
| -51% | -$202K | ﹤0.01% | 3794 |
|
|
2017
Q3 | $515K | Buy |
242,869
+8,326
| +4% | +$20.3K | ﹤0.01% | 3510 |
|
|
2017
Q2 | $680K | Sell |
234,543
-197
| -0.1% | -$591 | ﹤0.01% | 2935 |
|
|
2017
Q1 | $808K | Sell |
234,740
-23,612
| -9% | -$93.2K | ﹤0.01% | 3021 |
|
|
2016
Q4 | $449K | Sell |
258,352
-5,585
| -2% | -$13.1K | ﹤0.01% | 3501 |
|
|
2016
Q3 | $877K | Buy |
+263,937
| New | +$997K | ﹤0.01% | 3062 |
|
|
2016
Q2 | – | Sell |
-260,997
| Closed | -$1.47M | – | 4510 |
|
|
2016
Q1 | $1.47M | Buy |
260,997
+13,472
| +5% | +$175K | ﹤0.01% | 2433 |
|
|
2015
Q4 | $4.26M | Sell |
247,525
-132,980
| -35% | -$3.17M | ﹤0.01% | 1708 |
|
|
2015
Q3 | $8.03M | Sell |
380,505
-21,459
| -5% | -$735K | 0.01% | 1244 |
|
|
2015
Q2 | $19.9M | Buy |
401,964
+303,713
| +309% | +$18.2M | 0.02% | 844 |
|
|
2015
Q1 | $7.69M | Buy |
98,251
+41,721
| +74% | +$2.59M | 0.01% | 1363 |
|
|
2014
Q4 | $3.42M | Sell |
56,530
-68,527
| -55% | -$3.44M | ﹤0.01% | 2091 |
|
|
2014
Q3 | $5.33M | Buy |
125,057
+53,540
| +75% | +$2.88M | ﹤0.01% | 1713 |
|
|
2014
Q2 | $4.42M | Buy |
71,517
+43,457
| +155% | +$2.53M | ﹤0.01% | 2069 |
|
|
2014
Q1 | $1.82M | Sell |
28,060
-8,531
| -23% | -$577K | ﹤0.01% | 2590 |
|
|
2013
Q4 | $2.06M | Buy |
36,591
+25,132
| +219% | +$1.41M | ﹤0.01% | 2611 |
|
|
2013
Q3 | $703K | Buy |
11,459
+4,257
| +59% | +$288K | ﹤0.01% | 3249 |
|
|
2013
Q2 | $422K | Buy |
+7,202
| New | +$443K | ﹤0.01% | 3417 |
|
Other funds holding OREX
Credit Suisse's OREX Position: Q2 2018 in Review
Credit Suisse sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 165,770 shares — an estimated $35K sold.
Credit Suisse first reported a position in OREX in Q2 2013 and held it in 19 quarters. The position peaked at $19.9M in Q2 2015. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- Credit Suisse reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- Credit Suisse sold 165,770 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $35K.
- Credit Suisse first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Credit Suisse's Orexigen Therapeutics, Inc. position peaked at $19.9M in Q2 2015.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on Credit Suisse's 13F filing for Q2 2018, filed 14 Aug 2018.